Nathan Wages

Century City
  • 10250 Constellation Blvd.
  • Suite 1100
  • Los Angeles, CA 90067
  • USA
Profile Experience

Nathan Wages is an associate in the Century City office of Latham & Watkins and a member of the Corporate Department. He advises clients on a full spectrum of corporate matters, with an emphasis on technology transactions, mergers and acquisitions, intellectual property, general commercial matters, and corporate governance.

Mr. Wages represents both private and public companies in a range of matters, including:

  • Mergers and acquisitions
  • Commercial contracts and intellectual property licensing agreements
  • Private equity and venture capital transactions
  • Strategic alliances, partnerships, and joint ventures
  • Manufacture, supply, and distribution agreements
  • Customer and end-user arrangements
  • General corporate governance and compliance obligations under federal securities laws

Mr. Wages graduated from the University of Chicago Law School with Honors. Prior to law school, Mr. Wages received his BS in Biology and Biomedical Sciences from the University of Oklahoma and successfully completed two years of medical school at the University of Oklahoma.

Mr. Wages’ experience includes advising:

Mergers & Acquisitions and Capital Markets
  • Aspiration Partners in its US$2.3 billion deSPAC merger with InterPrivate III Financial Partners
  • Momenta Pharmaceuticals in its US$6.5 billion acquisition by Johnson & Johnson
  • CoStar Group in its acquisition of
  • William Lyon Homes in its US$2.4 billion acquisition by Taylor Morrison Home Corporation
  • Guardant Health in its US$1.15 billion convertible notes offering
  • Guardant Health in its US$1.11 billion common stock offering
Intellectual Property Guidance in Corporate Transactions
  • Traeger in its initial public offering
  • Amphenol Corporation in its US$1.7 billion acquisition of MTS Systems
  • Avery Dennison in its US$1.45 billion acquisition of Vestcom
  • CenterPoint Energy in its US$850 million sale of Miller Pipeline and Minnesota Limited
  • Ra Pharmaceuticals in its US$2.1 billion acquisition by UCB
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.